Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:MYH9-ALK (FusionGDB2 ID:HG4627TG238)

Fusion Gene Summary for MYH9-ALK

check button Fusion gene summary
Fusion gene informationFusion gene name: MYH9-ALK
Fusion gene ID: hg4627tg238
HgeneTgene
Gene symbol

MYH9

ALK

Gene ID

4627

238

Gene namemyosin heavy chain 9ALK receptor tyrosine kinase
SynonymsBDPLT6|DFNA17|EPSTS|FTNS|MATINS|MHA|NMHC-II-A|NMMHC-IIA|NMMHCACD246|NBLST3
Cytomap('MYH9')('ALK')

22q12.3

2p23.2-p23.1

Type of geneprotein-codingprotein-coding
Descriptionmyosin-9cellular myosin heavy chain, type Amyosin, heavy chain 9, non-musclenon-muscle myosin heavy chain 9non-muscle myosin heavy chain Anon-muscle myosin heavy chain IIanon-muscle myosin heavy polypeptide 9nonmuscle myosin heavy chain II-AALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase
Modification date2020031520200329
UniProtAcc

P35579

Q9UM73

Ensembl transtripts involved in fusion geneENST00000216181, ENST00000401701, 
ENST00000475726, 
Fusion gene scores* DoF score55 X 51 X 22=6171056 X 74 X 20=82880
# samples 7757
** MAII scorelog2(77/61710*10)=-6.32450203855119
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(57/82880*10)=-7.18391827352181
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: MYH9 [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpoint
Anticipated loss of major functional domain due to fusion event.MYH9-ALK seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
MYH9-ALK seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
MYH9-ALK seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
MYH9-ALK seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
MYH9-ALK seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMYH9

GO:0001525

angiogenesis

16403913

HgeneMYH9

GO:0001778

plasma membrane repair

27325790

HgeneMYH9

GO:0006509

membrane protein ectodomain proteolysis

16186248

HgeneMYH9

GO:0030048

actin filament-based movement

12237319|15845534

HgeneMYH9

GO:0031032

actomyosin structure organization

24072716

TgeneALK

GO:0016310

phosphorylation

9174053

TgeneALK

GO:0046777

protein autophosphorylation

9174053



check button Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerKB3..MYH9chr22

36684297

-ALKchr2

29446394

-


Top

Fusion Gene ORF analysis for MYH9-ALK

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
5CDS-intronENST00000216181ENST00000431873MYH9chr22

36684297

-ALKchr2

29446394

-
5CDS-intronENST00000216181ENST00000498037MYH9chr22

36684297

-ALKchr2

29446394

-
Frame-shiftENST00000216181ENST00000389048MYH9chr22

36684297

-ALKchr2

29446394

-
intron-3CDSENST00000401701ENST00000389048MYH9chr22

36684297

-ALKchr2

29446394

-
intron-3CDSENST00000475726ENST00000389048MYH9chr22

36684297

-ALKchr2

29446394

-
intron-intronENST00000401701ENST00000431873MYH9chr22

36684297

-ALKchr2

29446394

-
intron-intronENST00000401701ENST00000498037MYH9chr22

36684297

-ALKchr2

29446394

-
intron-intronENST00000475726ENST00000431873MYH9chr22

36684297

-ALKchr2

29446394

-
intron-intronENST00000475726ENST00000498037MYH9chr22

36684297

-ALKchr2

29446394

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for MYH9-ALK


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)


Top

Fusion Protein Features for MYH9-ALK


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:/:)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
MYH9

P35579

ALK

Q9UM73

FUNCTION: Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Promotes also cell motility together with S100A4 (PubMed:16707441). During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the margins but not the central part of spreading cells), and lamellipodial retraction; this function is mechanically antagonized by MYH10 (PubMed:20052411). {ECO:0000250|UniProtKB:Q8VDD5, ECO:0000269|PubMed:16707441, ECO:0000269|PubMed:20052411}.FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. Thinness gene involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). {ECO:0000250|UniProtKB:P97793, ECO:0000269|PubMed:11121404, ECO:0000269|PubMed:11278720, ECO:0000269|PubMed:11387242, ECO:0000269|PubMed:11809760, ECO:0000269|PubMed:12107166, ECO:0000269|PubMed:12122009, ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15908427, ECO:0000269|PubMed:16317043, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:17274988}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for MYH9-ALK


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

Top

Fusion Gene PPI Analysis for MYH9-ALK


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for MYH9-ALK


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneALKQ9UM73DB08865CrizotinibInhibitorSmall moleculeApproved
TgeneALKQ9UM73DB09063CeritinibAntagonistSmall moleculeApproved
TgeneALKQ9UM73DB11363AlectinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12130LorlatinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12141GilteritinibInhibitorSmall moleculeApproved|Investigational
TgeneALKQ9UM73DB12267BrigatinibInhibitorSmall moleculeApproved|Investigational

Top

Related Diseases for MYH9-ALK


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneMYH9C0340978May-Hegglin anomaly25CLINGEN;GENOMICS_ENGLAND;UNIPROT
HgeneMYH9C1854520SEBASTIAN SYNDROME14CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneMYH9C0398641Epstein syndrome (disorder)11CLINGEN
HgeneMYH9C0403445Fechtner syndrome (disorder)11CLINGEN
HgeneMYH9C0477317Other primary thrombocytopenia11CLINGEN
HgeneMYH9C1842035Giant Platelet Syndrome with Thrombocytopenia11CLINGEN
HgeneMYH9C1863659DEAFNESS, AUTOSOMAL DOMINANT 176CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneMYH9C0022661Kidney Failure, Chronic2CTD_human
HgeneMYH9C0006142Malignant neoplasm of breast1CTD_human;UNIPROT
HgeneMYH9C0017668Focal glomerulosclerosis1CTD_human
HgeneMYH9C0018784Sensorineural Hearing Loss (disorder)1GENOMICS_ENGLAND
HgeneMYH9C0018965Hematuria1GENOMICS_ENGLAND
HgeneMYH9C0020544Renal hypertension1CTD_human
HgeneMYH9C0027626Neoplasm Invasiveness1CTD_human
HgeneMYH9C0027706Hereditary nephritis1CTD_human
HgeneMYH9C0033687Proteinuria1GENOMICS_ENGLAND
HgeneMYH9C0035078Kidney Failure1GENOMICS_ENGLAND
HgeneMYH9C0086432Hyalinosis, Segmental Glomerular1CTD_human
HgeneMYH9C0086543Cataract1GENOMICS_ENGLAND
HgeneMYH9C0206692Carcinoma, Lobular1CTD_human
HgeneMYH9C0410005Nodular fasciitis1ORPHANET
HgeneMYH9C0678222Breast Carcinoma1CTD_human
HgeneMYH9C1257931Mammary Neoplasms, Human1CTD_human
HgeneMYH9C1458155Mammary Neoplasms1CTD_human
HgeneMYH9C1567741Alport Syndrome1CTD_human
HgeneMYH9C1567742Alport Syndrome, X-Linked1CTD_human
HgeneMYH9C1567743Alport Syndrome, Autosomal Dominant1CTD_human
HgeneMYH9C1567744Alport Syndrome, Autosomal Recessive1CTD_human
HgeneMYH9C1834478MACROTHROMBOCYTOPENIA AND PROGRESSIVE SENSORINEURAL DEAFNESS1CTD_human
HgeneMYH9C2931861Hemorrhagic hereditary nephritis1CTD_human
HgeneMYH9C4280711Leukocyte inclusion bodies1GENOMICS_ENGLAND
HgeneMYH9C4704874Mammary Carcinoma, Human1CTD_human
TgeneC0007131Non-Small Cell Lung Carcinoma28CGI;CTD_human
TgeneC0027819Neuroblastoma13CGI;CTD_human;ORPHANET
TgeneC0152013Adenocarcinoma of lung (disorder)8CGI;CTD_human
TgeneC2751681NEUROBLASTOMA, SUSCEPTIBILITY TO, 38CLINGEN;UNIPROT
TgeneC0206180Ki-1+ Anaplastic Large Cell Lymphoma6CGI;CTD_human
TgeneC0334121Inflammatory Myofibroblastic Tumor4CGI;CTD_human;ORPHANET
TgeneC0018199Granuloma, Plasma Cell3CTD_human
TgeneC0007621Neoplastic Cell Transformation2CTD_human
TgeneC0027627Neoplasm Metastasis2CTD_human
TgeneC0238463Papillary thyroid carcinoma2ORPHANET
TgeneC0001973Alcoholic Intoxication, Chronic1PSYGENET
TgeneC0006118Brain Neoplasms1CGI;CTD_human
TgeneC0006142Malignant neoplasm of breast1CTD_human
TgeneC0007134Renal Cell Carcinoma1CTD_human
TgeneC0011570Mental Depression1PSYGENET
TgeneC0011581Depressive disorder1PSYGENET
TgeneC0027643Neoplasm Recurrence, Local1CTD_human
TgeneC0036341Schizophrenia1PSYGENET
TgeneC0079744Diffuse Large B-Cell Lymphoma1CTD_human
TgeneC0085269Plasma Cell Granuloma, Pulmonary1CTD_human
TgeneC0153633Malignant neoplasm of brain1CGI;CTD_human
TgeneC0278601Inflammatory Breast Carcinoma1CTD_human
TgeneC0279702Conventional (Clear Cell) Renal Cell Carcinoma1CTD_human
TgeneC0496899Benign neoplasm of brain, unspecified1CTD_human
TgeneC0678222Breast Carcinoma1CTD_human
TgeneC0750974Brain Tumor, Primary1CTD_human
TgeneC0750977Recurrent Brain Neoplasm1CTD_human
TgeneC0750979Primary malignant neoplasm of brain1CTD_human
TgeneC1257931Mammary Neoplasms, Human1CTD_human
TgeneC1266042Chromophobe Renal Cell Carcinoma1CTD_human
TgeneC1266043Sarcomatoid Renal Cell Carcinoma1CTD_human
TgeneC1266044Collecting Duct Carcinoma of the Kidney1CTD_human
TgeneC1306837Papillary Renal Cell Carcinoma1CTD_human
TgeneC1332079Anaplastic Large Cell Lymphoma, ALK-Positive1ORPHANET
TgeneC1458155Mammary Neoplasms1CTD_human
TgeneC1527390Neoplasms, Intracranial1CTD_human
TgeneC2931189Neural crest tumor1ORPHANET
TgeneC3899155hereditary neuroblastoma1GENOMICS_ENGLAND
TgeneC4704874Mammary Carcinoma, Human1CTD_human